Supplementary file 3: Diagnostic validity scores for the retained high quality RCTs

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Inclusion criteria | | | | | Exclusion criteria | | | | | | | |  | |  | |
| Study | A | B | | C | | D | | E | | F | | G | | *Total* | |  | |
| **Previous search (29 trials)** |  | | | | | | | | | | | | | | | |
| Baldon 2014 | 1 | | 1 | | 1 | | 1 | | 1 | | 1 | | 1 | | 7 | |
| Behrangrad 2017 | 0 | | 0 | | 1 | | 1 | | 1 | | 1 | | 0 | | 4 | |
| Bolgla 2016 | 0 | | 0 | | 1 | | 0 | | 0 | | 1 | | 1 | | 3 | |
| Celik 2020 | 1 | | 0 | | 1 | | 1 | | 1 | | 1 | | 0 | | 5 | |
| Clark 2000 | 0 | | 0 | | 0 | | 0 | | 1 | | 1 | | 0 | | 2 | |
| Collins 2008 | 1 | | 1 | | 1 | | 1 | | 0 | | 1 | | 0 | | 5 | |
| Crossley 2002 | 1 | | 1 | | 1 | | 1 | | 1 | | 1 | | 1 | | 7 | |
| Das 2016 | 1 | | 0 | | 1 | | 1 | | 1 | | 1 | | 1 | | 6 | |
| Espi-Lopez 2017 | 1 | | 1 | | 1 | | 1 | | 1 | | 1 | | 0 | | 6 | |
| Fukuda 2010 | 0 | | 0 | | 1 | | 1 | | 1 | | 1 | | 1 | | 5 | |
| Fukuda 2012 | 0 | | 0 | | 1 | | 1 | | 1 | | 1 | | 1 | | 5 | |
| Garcia-Triana 2021 | 0 | | 0 | | 0 | | 0 | | 1 | | 1 | | 1 | | 3 | |
| Halabchi 2015 | 1 | | 0 | | 1 | | 1 | | 1 | | 1 | | 1 | | 6 | |
| Hott 2019 | 0 | | 0 | | 1 | | 1 | | 1 | | 1 | | 1 | | 5 | |
| Hott 2020 | 0 | | 0 | | 1 | | 1 | | 1 | | 1 | | 1 | | 5 | |
| Ismail 2013 | 1 | | 1 | | 1 | | 1 | | 1 | | 1 | | 0 | | 6 | |
| Matthews 2020 | 1 | | 1 | | 1 | | 1 | | 0 | | 1 | | 0 | | 5 | |
| Molgaard 2018 | 1 | | 0 | | 0 | | 1 | | 1 | | 0 | | 1 | | 4 | |
| Motealleh 2019 | 0 | | 0 | | 1 | | 1 | | 1 | | 1 | | 1 | | 5 | |
| Nakagawa 2013 | 1 | | 1 | | 1 | | 1 | | 1 | | 1 | | 1 | | 7 | |
| Rasti 2020 | 0 | | 1 | | 1 | | 1 | | 1 | | 1 | | 1 | | 6 | |
| Saad 2018 | 1 | | 1 | | 1 | | 1 | | 0 | | 1 | | 0 | | 5 | |
| Sahin 2016 | 1 | | 1 | | 1 | | 1 | | 1 | | 1 | | 1 | | 7 | |
| Song 2009 | 1 | | 1 | | 1 | | 1 | | 1 | | 0 | | 1 | | 6 | |
| van den Dolder 2006 | 0 | | 0 | | 0 | | 1 | | 0 | | 0 | | 0 | | 1 | |
| Wu 2021 | 1 | | 1 | | 1 | | 1 | | 1 | | 1 | | 1 | | 7 | |
| Yanez-Alvarez 2020 | 0 | | 1 | | 1 | | 1 | | 1 | | 1 | | 1 | | 6 | |
| Zago 2021 | 0 | | 0 | | 1 | | 0 | | 0 | | 0 | | 0 | | 1 | |
| Zarei 2020 | 1 | | 1 | | 1 | | 0 | | 1 | | 1 | | 1 | | 6 | |
| **Updated search (5 trials)** |  | |  | |  | |  | |  | |  | |  | |  | |
| Hansen 2023 | 0 | | 1 | | 1 | | 1 | | 1 | | 1 | | 1 | | 6 | |
| Kumar 2023 | 1 | | 0 | | 1 | | 0 | | 1 | | 0 | | 1 | | 4 | |
| Pompeo 2022 | 1 | | 0 | | 1 | | 1 | | 1 | | 1 | | 1 | | 6 | |
| Silva 2023 | 0 | | 0 | | 1 | | 1 | | 0 | | 0 | | 1 | | 3 | |
| Zafarian 2023 | 0 | | 0 | | 1 | | 1 | | 1 | | 1 | | 0 | | 4 | |

*A – pain location; B – insidious onset; C – symptoms consistent with PFP; D – previous knee surgery; E – internal derangement;*

*F – ligamentous instability; G – other sources of knee pain*